Hologic Inc. Company Profile

Sr. No.

Item

Description

1

Company Name

Hologic, Inc.

2

Website

https://www.hologic.com/

3

Established Date

1985

4

Headquartered

United States

5

Market Position/ History

Hologic, Inc. has a long history of pioneering innovations in healthcare, particularly in women’s health. Since its founding, the company has developed groundbreaking medical technologies, including the first nucleic acid test (1985) and dual-energy X-ray absorptiometry system for osteoporosis (1987). Hologic revolutionized cervical cancer screening with the ThinPrep Pap test (1996) and introduced the NovaSure endometrial ablation system (2001) for treating abnormal uterine bleeding.

The company expanded its diagnostic capabilities with the approval of molecular diagnostic tests for sexually transmitted infections, blood screening, and respiratory assays. In response to the COVID-19 pandemic, Hologic developed diagnostic tests for SARS-CoV-2 in 2020.

Throughout its history, Hologic has remained dedicated to improving women’s health through technology and diagnostic solutions, shaping the future of healthcare with a focus on precision and patient comfort.

6

Sales Area

Worldwide

7

Manufacturing Location

Worldwide

8

Ticker

NASDAQ: HOLX

9

No. of Employees

7,000

10

Competitors

• Becton, Dickinson and Company (BD)
• Medtronic Inc.
• Stryker Corporation
• Olympus Europa SE & Co. KG

11

CEO

Stephen P. MacMillan

12

Ownership Type

Public

13

Contact Information

250 Campus Drive, Marlborough, MA 01752

Tel: (01) 508.263.2900

Product

Product Description

Acessa ProVu System

The Acessa ProVu System is designed for percutaneous, laparoscopic coagulation and ablation of soft tissue, specifically for treating symptomatic uterine fibroids under laparoscopic ultrasound guidance. The system offers optional electromagnetic guidance to enhance the ultrasonic image of the Acessa ProVu Handpiece and predict its future path on a computer monitor, which also displays the ultrasound B-scan image.

This integrated system combines radiofrequency (RF) ablation, ultrasound, and guidance capabilities within a single console and includes additional accessories. It delivers monopolar RF energy to tissue through a disposable Handpiece and can provide up to 200W of power. The Acessa ProVu System’s console is designed exclusively for use with Acessa Health-manufactured devices. It features temperature or power display, depending on the mode used, to help physicians monitor and control the ablation during the procedure.

The system operates under laparoscopic ultrasound guidance, using ultrasound wave pulses to capture echo data, which is then used to create B-mode images on the monitor. The Acessa ProVu System Transducer (5-12 MHz) is used for imaging. Additionally, the Acessa Guidance System, an advanced electromagnetic spatial tracking system, tracks the position and orientation of sensors embedded in the tip of the Handpiece and Transducer with Sensor. This allows the system to calculate their position within the abdominal cavity and display an animated image on a monitor.

The Acessa ProVu System consists of a console with the following components: an RF ablation system, an ultrasound system, and a guidance system.

Benefits of the Acessa ProVu System:

• The first and only fully integrated system combining laparoscopic ultrasound, guidance mapping, and radiofrequency ablation.
• Developed by a gynecologist specifically for uterine fibroids.
• Identifies 1.5 to 2.0 times more fibroids than preoperative TVUS and MRI.
• Provides the most comprehensive view of fibroids, allowing surgeons to identify more fibroids than any other uterine-sparing, minimally invasive procedure.
• Includes a laparoscopic-specific category 1 CPT code (58674) with favorable reimbursement.
• Demonstrates an 11% cumulative 3-year reintervention rate.

Year

Latest News

August 2020

Hologic, Inc. Acquired Acessa Health to Expand Fibroid Treatment Portfolio

Hologic, Inc. has acquired Acessa Health Inc., a leader in minimally invasive fibroid treatment, for $80 million in cash plus contingent payments. This acquisition strengthens Hologic's position in the GYN surgical market and enhances its fibroid treatment portfolio with the Acessa ProVu system, a laparoscopic technology that combines radiofrequency ablation with ultrasound guidance. The system offers a minimally invasive alternative to traditional fibroid treatments, providing benefits like reduced blood loss and faster recovery. This acquisition aligns with Hologic’s growth strategy and aims to improve clinical outcomes for women with uterine fibroids.

November 2022

Humber River Health (Humber) has launched the use of the Acessa ProVu system – a new way to treat uterine fibroids.

Humber River Health (Humber) has introduced the Acessa ProVu system, a minimally invasive treatment for uterine fibroids, becoming one of only two centers in Canada to offer this approach. Uterine fibroids are common benign tumors affecting up to 70% of women during their reproductive years, with around 30% of those experiencing symptoms such as abnormal bleeding, pelvic pain, and difficulty with pregnancy. While mild cases often don’t require treatment, severe symptoms are typically managed through surgeries like hysterectomy or myomectomy.

The Acessa ProVu system offers a novel, non-invasive solution by using radiofrequency ablation, laparoscopic ultrasound, and monopolar cautery. Developed by Dr. Bruce B. Lee, the system targets fibroids of various sizes and locations, shrinking them without the need for incisions or uterine cuts. The procedure preserves healthy uterine tissue by destroying fibroid proteins with heat, causing the fibroid to shrink and reabsorb over time. With minimal post-operative pain and a quick recovery, patients can return to normal activities faster. Additionally, the procedure requires only two to three small incisions, making it cosmetically advantageous.